Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma

被引：0
|
作者：
陈智 [1 ]
机构：
[1] Dept Hematol,1st Affil Hosp,Nanjing Med Univ
来源：
ChinaMedicalAbstracts(InternalMedicine) | 2022年 / 39卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R733.3 [骨髓肿瘤];
学科分类号：
摘要：
Objective To investigate the influence of the number of high-risk cytogenetic abnormalities (HRCA)on the clinical characteristics and prognosis of patients with newly diagnosed multiple myeloma (MM).Methods A total of 360 patients with newly diagnosed MM admitted to Jiangsu Province Hospital between November 2013 and September 2020 were included in this study. Cytoplasmic light chain immunofluorescence with fluorescence in situ hybridization (cIg-FISH) was used to detect HRCA. Cytogenetic abnormalities were combined with clinical characteristics and outcomes for further analysis. Results Among the 360 patients,120patients (33.3%) didn’t present with HRCAs,and 175(48.6%),61 (16.9%),and four (1.1%) patients had one, two, and three HRCA (s), respectively.
引用
收藏
页码：182 / 183
页数：2
相关论文
共 50 条
  • [1] PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    HAEMATOLOGICA, 2017, 102 : 107 - 107
  • [2] Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma
    Binder, Moritz
    Rajkumar, S. Vincent
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Hwa, Yi L.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kyle, Robert A.
    Kumar, Shaji
    BLOOD, 2016, 128 (22)
  • [3] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
    M Binder
    S V Rajkumar
    R P Ketterling
    P T Greipp
    A Dispenzieri
    M Q Lacy
    M A Gertz
    F K Buadi
    S R Hayman
    Y L Hwa
    S R Zeldenrust
    J A Lust
    S J Russell
    N Leung
    P Kapoor
    R S Go
    W I Gonsalves
    R A Kyle
    S K Kumar
    Blood Cancer Journal, 2017, 7 : e600 - e600
  • [4] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Greipp, P. T.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    BLOOD CANCER JOURNAL, 2017, 7 : e600 - e600
  • [5] Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study
    Liang, Dong
    Li, Xiaojin
    Bai, Shenrui
    Wang, Qiaoli
    Zeng, Min
    Feng, Demei
    Lu, Bo
    Li, Xiaoqing
    Sun, Zhiqiang
    Li, Jianyun
    Zhou, Huanhuan
    Zhang, Jialu
    Chen, Xiaoqin
    Xia, Zhongjun
    Liang, Yang
    Wang, Hua
    CANCER MEDICINE, 2024, 13 (20):
  • [6] Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities
    Cavo, Michele
    Bringhen, Sara
    Terragna, Carolina
    Omede, Paola
    Marzocchi, Giulia
    Ruggeri, Marina
    Durante, Sandra
    Petrucci, Maria Teresa
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Montefusco, Vittorio
    Narni, Franco
    Falcone, Antonietta
    Califano, Catello
    Baraldi, Anna
    Pasini, Silvana
    Galieni, Piero
    Morabito, Fortunato
    Grasso, Mariella
    Gottardi, Daniela
    Rizzo, Vincenzo
    Boccadoro, Mario
    Testoni, Nicoletta
    Palumbo, Antonio
    BLOOD, 2010, 116 (21) : 342 - 343
  • [7] Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study
    Liang, Dong
    Feng, Demei
    Wang, Qiaoli
    Bai, Shenrui
    Zeng, Min
    Lu, Bo
    Li, Xiaoqing
    Sun, Zhiqiang
    Li, Jianyun
    Zhou, Huanhuan
    Zhang, Jialu
    Chen, Xiaoqin
    Xia, Zhongjun
    Liang, Yang
    Wang, Hua
    BLOOD, 2024, 144 : 7064 - 7065
  • [8] Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients
    Mao, Xuehan
    Xu, Yan
    Yan, Yuting
    Liu Jiahui
    Fan Huishou
    Sui Weiwei
    Zengjun, Lizengjun
    Deng, Shuhui
    Yi, Shuhua
    Wang, Tingyu
    Wang, Qi
    Liu, Hui-Min
    Qiu, Lugui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E83 - E83
  • [9] High risk cytogenetic abnormalities in patients with multiple myeloma
    Eugenia Legues, Maria
    Morales, Paulina
    Valenzuela, Mercedes
    Encina, Andrea
    Jose Marti, Maria
    Bascunan, Claudia
    Cornejo, Paulina
    Pena, Camila
    Soledad Undurraga, Maria
    REVISTA MEDICA DE CHILE, 2019, 147 (01) : 61 - 64
  • [10] Overexpression of Integrin ß7 in Newly Diagnosed Multiple Myeloma with High Risk Cytogenetic Abnormality and Poorer Prognosis
    Zheng, Dong
    Wan, Wenli
    Zhu, Mingxia
    Jing, Hongmei
    BLOOD, 2023, 142
12345